Puma Biotechnology (PBYI) to Release Quarterly Earnings on Thursday

Puma Biotechnology (NASDAQ:PBYI) is expected to post its quarterly earnings results after the market closes on Thursday, February 27th. Analysts expect Puma Biotechnology to post earnings of $0.10 per share and revenue of $52.50 million for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Puma Biotechnology Stock Down 0.3 %

Shares of Puma Biotechnology stock opened at $2.89 on Tuesday. Puma Biotechnology has a 12 month low of $2.22 and a 12 month high of $7.15. The company has a quick ratio of 1.40, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. The stock has a market cap of $141.86 million, a PE ratio of 6.02 and a beta of 1.09. The business has a fifty day simple moving average of $3.00 and a 200 day simple moving average of $2.87.

Insider Activity

In related news, CEO Alan H. Auerbach sold 33,841 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total transaction of $106,599.15. Following the sale, the chief executive officer now owns 7,029,674 shares of the company’s stock, valued at $22,143,473.10. This represents a 0.48 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Jeffrey Jerome Ludwig sold 9,437 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total value of $29,726.55. Following the sale, the insider now directly owns 108,951 shares in the company, valued at $343,195.65. This represents a 7.97 % decrease in their position. The disclosure for this sale can be found here. 23.70% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on PBYI. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Puma Biotechnology in a report on Monday, December 23rd. StockNews.com lowered Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Friday, December 6th.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.